ClinicalTrials.gg
RecruitingNCT05976152Be-CLEVERUpdated Apr 15, 2024

Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)

A Phase 3 interventional study of dl-3-butylphthalide and dl-3-butylphthalide placebo in Stroke and Post-stroke Cognitive Impairment (PSCI), sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,200
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
38th of 432
3,200 · median 169
Started
2024
with 70 others
Phase 3
62 of 613
16 open now
Primary completion
2026-12
later than 120 of 262 live
Registered
350th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 38th largest by planned enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 62 in phase 3, reaches primary completion later than 120 of the 262 other live ones, and was the 350th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

Post-stroke cognitive impairment (PSCI) refers to a clinical syndrome characterized by cognitive impairment that occurs after a stroke event and persists for at least 24 weeks. Due to the early recovery of conditions such as delirium and transient cognitive impairment after stroke, the diagnosis of PSCI often requires cognitive assessment at 12 to 24 weeks post-stroke to determine the severity of cognitive impairment. It can be classified according to the severity of cognitive impairment as post-stroke cognitive impairment no dementia (PSCIND) and post-stroke dementia (PSD). Recent large international cohort studies have reported an incidence rate of PSCI ranging from 24% to 53.4%, and patients with PSCI have a significantly higher mortality rate compared to those without cognitive impairment. Guidelines such as American Heart Association/American Society of Anesthesiologists (AHA/ASA) and the Chinese "Expert Consensus on the Management of Post-Stroke Cognitive Impairment" propose integrating cognitive impairment and stroke intervention strategies. Early comprehensive intervention and treatment for high-risk individuals after stroke, aiming to delay or prevent the progression from PSCIND to PSD, are the primary goals in the current treatment of PSCI. However, there is currently a lack of large randomized controlled trials (RCTs) for PSCI, and research is still needed to determine whether cognitive-enhancing drugs can reduce the risk of PSCI occurrence and improve outcomes and prognosis for PSCI patients. A randomized, double-blind, multicenter clinical study involving 281 non-dementia vascular cognitive impairment (VCI) patients showed that the overall cognitive scores of patients treated with donepezil for 24 weeks significantly improved compared to the placebo group.

The aim of this study is to evaluate the effectiveness of donepezil in the treatment of post-stroke cognitive impairment. It will be a multicenter, randomized, double-blind, placebo-controlled trial with a 48-week treatment duration. The study will observe the difference in PSCI incidence rate between the donepezil treatment group and the conventional stroke treatment group at 24 weeks and evaluate the improvement in post-stroke cognitive impairment after 6 months of donepezil treatment compared to conventional treatment.

This study will be conducted in two stages: the first stage (0-24 weeks) aims to assess whether donepezil can reduce the risk of PSCI occurrence and will be a multicenter, randomized, double-blind, placebo-controlled study. The second stage (24-48 weeks) aims to evaluate whether donepezil can improve the prognosis of PSCI patients and will also be a multicenter, randomized, double-blind, placebo-controlled study.

03

Conditions studied

  • Stroke
  • Post-stroke Cognitive Impairment (PSCI)

Browse trials for

Keywords

  • stroke
  • PSCI
  • Butylphthalide
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First stage:

  • Acute ischemic stroke (AIS) symptom onset within 14 days Signs and symptoms consistent with the diagnosis of an acute ischemic stroke by CT/MRI.
  • Age >= 60 years,
  • Baseline NIHSS 3-18.
  • Patient can complete questionnaire survey, physical examination, cranial MRI and other medical examinations
  • Patient/legally authorized representative has signed the Form

Second stage:

  • Patient with stage I diagnosis of PSCI.
  • Patient can complete questionnaire survey, physical examination, cranial MRI and other medical examinations.
  • Patient/legally authorized representative has signed the Informed Consent Form

Exclusion criteria

Exclusion Criteria:

First stage:

  • Patients who had been diagnosed with dementia prior to stroke
  • Other related factors affecting cognitive function: central nervous system infection, neurodegenerative diseases, trauma, poisoning, intracranial space occupying lesions, metabolic diseases, etc.
  • Other serious central nervous system diseases: Parkinson's disease, epilepsy, multiple sclerosis, motor neurone disease, immune-related encephalomyelopathy, etc.
  • Serious mental illness: anxiety disorder, depression, delirium, schizophrenia, bipolar disorder, mental retardation, which is diagnosed or controlled by medication.
  • Uncorrectable visual and hearing impairments and inability to complete neuropsychological tests
  • Severe liver and kidney dysfunction
  • The presence of a malignant tumor or other serious/life-threatening disease that could cause the subject's death within 12 months.
  • Current known alcohol or illicit drug abuse or dependence
  • Patients undergoing thrombectomy, thrombolysis, carotid endarterectomy, or other surgical procedures during the acute infarction.
  • Using cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonists, or Sodium oligomannate (GV-971).
  • Allergic to any component of butylphthalein
  • Pregnancy or lactation, have the possibility of becoming pregnant, and who plan to become pregnant
  • Participants in other interventional clinical trials
  • MRI (e.g., claustrophobia, to contrast media, etc.)

Second stage:

  • During the first phase of follow-up, participants' compliance was poor, with study medication compliance less than 80% or greater than 120%; Follow-up was less than 24 weeks or did not complete the follow-up within the follow-up window..
  • Recurrent stroke in the first stage
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,200 participants (estimated)

Study arms

  • Experimental
    dl-3-butylphthalide

    Routine treatment and dl-3-butylphthalide

    Drug: dl-3-butylphthalide · Drug: dl-3-butylphthalide placebo

  • Placebo comparator
    dl-3-butylphthalide Placebo

    Routine treatment and dl-3-butylphthalide Placebo

    Drug: dl-3-butylphthalide · Drug: dl-3-butylphthalide placebo

Interventions

  • DrugButylphthalideStudies of ButylphthalideButylphthalide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    First stage: Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs. Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Second stage: 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.

    Also known as: DL-3-n-butylphthalide (NBP)

  • Drugdl-3-butylphthalide placebo

    First stage: Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs. Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Second stage: 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.

    Also known as: NBP placebo

06

What researchers measure

Primary outcomes

  1. PSCI incidence

    Compared with routine stroke treatment, the difference of the PSCI incidence at 24 weeks with butylphthalide treatment.

    Time frame: 24 weeks (first stage)

  2. vadas-cog score

    Compared with routine treatment, improvement of vadas-cog scores at 24 weeks with butylphthalide treatment

    Time frame: 6 months (Second stage)

Secondary outcomes

  1. Changes of Montreal Cognitive Assessment (MoCA) at 24 weeks compared with baseline

    Changes of Montreal Cognitive Assessment (MoCA) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  2. Changes of Mini-Mental State Examination (MMSE) at 24 weeks compared with baseline

    Changes of Mini-Mental State Examination (MMSE) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  3. Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 24 weeks compared with baseline

    Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  4. Changes of Hamilton Anxiety Scale (HAMA) at 24 weeks compared with baseline

    Changes of Hamilton Anxiety Scale (HAMA) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  5. Changes of Hamilton Depression Scale (HAMD) at 24 weeks compared with baseline

    Changes of Hamilton Depression Scale (HAMD) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  6. Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 24 weeks compared with baseline

    Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  7. Changes of Clinical Dementia Rating (CDR) at 24 weeks compared with baseline

    Changes of Clinical Dementia Rating (CDR) at 24 weeks compared with baseline

    Time frame: 24 weeks (first stage)

  8. Changes of infarct volume by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.

    Changes of infarct volume by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.

    Time frame: 24 weeks (first stage)

  9. Changes of infarct location by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.

    Changes of infarct location by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.

    Time frame: 24 weeks (first stage)

  10. stroke recurrence

    Difference in stroke recurrence rate of butylphthalein treatment compared with routine stroke treatment at 24 weeks

    Time frame: 24 weeks (first stage)

  11. Changes of modified Rankin Scale score (mRS) at 24 weeks compared with baseline.

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS is a range from 0-6. 0=No symptoms, 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead

    Time frame: 24 weeks (first stage)

  12. Changes of Montreal Cognitive Assessment (MoCA) at 48 weeks compared with baseline

    Changes of Montreal Cognitive Assessment (MoCA) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  13. Changes of Mini-Mental State Examination (MMSE) at 48 weeks compared with baseline

    Changes of Mini-Mental State Examination (MMSE) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  14. Changes cognitive domain level by Symbol Digit Modalities Test at 48 weeks compared with baselinel

    Changes cognitive domain level by Symbol Digit Modalities Test at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  15. Changes cognitive domain level by Trail Making Test at 48 weeks compared with baseline.

    Changes cognitive domain level by Trail Making Test at 48 weeks compared with baseline.

    Time frame: 48 weeks (second stage)

  16. Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 48 weeks compared with baseline

    Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  17. Changes of Hamilton Anxiety Scale (HAMA) at 48 weeks compared with baseline

    Changes of Hamilton Anxiety Scale (HAMA) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  18. Changes of Hamilton Depression Scale (HAMD) at 48 weeks compared with baseline

    Changes of Hamilton Depression Scale (HAMD) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  19. Changes of Clinical Dementia Rating (CDR) at 48 weeks compared with baseline

    Changes of Clinical Dementia Rating (CDR) at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  20. Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 48 weeks compared with baseline

    Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 48 weeks compared with baseline

    Time frame: 48 weeks (second stage)

  21. stroke recurrence

    Difference in stroke recurrence rate of butylphthalein treatment compared with routine stroke treatment at 48 weeks

    Time frame: 48 weeks (second stage)

  22. Changes of mRS at 48 weeks compared with baseline.

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS is a range from 0-6. 0=No symptoms, 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead

    Time frame: 48 weeks (second stage)

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety]

    Incidence of Treatment-Emergent Adverse Events \[Safety\]

    Time frame: 12 weeks, 24 weeks, 36 weeks and 48 weeks

  2. Dropout rates and reasons [Safety]

    Dropout rates and reasons \[Safety\]

    Time frame: 12 weeks, 24 weeks, 36 weeks and 48 weekss

07

Study locations

1 of 1 sites recruiting
  • Donggang Center Hospitol
    Dandong, Liaoning, China
    Recruiting
    • Lili wang · Contact15842554006
    • Jing Li · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Dec 2026, 32 months later.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 32 months is below that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Aug 4, 2023
StartEst.
Apr 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05976152
Lead sponsor
Fudan University
Responsible party
Qiang Dong (Director of Neurology Department, Huashan Hospital, Huashan Hospital) — Principal investigator
First posted
Aug 4, 2023
Start date
Apr 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 15, 2024

Study contacts

Qiang Dong
Contact
dong_qiang@fudan.edu.cn
+8602152887145

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Butylphthalide

Start the discussion